Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after …

R Kaartama, P Jarho, J Savolainen, H Kokki… - … of Chromatography B, 2011 - Elsevier
A sensitive and selective gas chromatographic mass spectrometric method for the
determination of midazolam and its biologically active metabolite, 1-hydroxymidazolam, in …

Maturational changes in the in vivo activity of CYP3A4 in the first months of life.

K Allegaert, JN Van den Anker… - … Journal of Clinical …, 2006 - search.ebscohost.com
Objective: To document maturational changes of the in vivo activity of CYP3A4 in the first
months of life. Methods: The contribution of tramadol (M), O-demethyl tramadol (M1 …

Neonatal clinical pharmacology

K Allegaert, M van de Velde… - Pediatric …, 2014 - Wiley Online Library
Effective and safe drug administration in neonates should be based on integrated
knowledge on the evolving physiological characteristics of the infant who will receive the …

Prediction of midazolam—cyp3a inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data

K Yamano, K Yamamoto, M Katashima, H Kotaki… - Drug Metabolism and …, 2001 - ASPET
The extent of decreases in apparent hepatic clearance and intrinsic hepatic clearance of
midazolam (MDZ) after intravenous administration of MDZ with concomitant oral …

Neonatal pharmacology and pharmacokinetics

PD Reiter - NeoReviews, 2002 - publications.aap.org
Objectives After completing this article, readers should be able to: 1. Summarize the impact
of gestational age, postnatal age, and disease state on drug absorption, distribution …

Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug–drug interactions

F Salem, TN Johnson, ZE Barter… - The Journal of …, 2013 - Wiley Online Library
The magnitude of any metabolic drug–drug interactions (DDIs) depends on fractional
importance of inhibited pathway which may not necessarily be the same in young children …

Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants

EHJ Krekels, S Van Ham, K Allegaert… - European journal of …, 2015 - Springer
Purpose Based on recovered metabolite ratios in urine, it has been concluded that
paracetamol glucuronidation may be up-regulated upon multiple dosing. This study …

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children

TN Johnson, A Rostami-Hodjegan, GT Tucker - Clinical pharmacokinetics, 2006 - Springer
Background Prediction of the exposure of neonates, infants and children to xenobiotics is
likely to be more successful using physiologically based pharmacokinetic models than …

[PDF][PDF] The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs

C Arellano, C Philibert, C Vachoux, J Woodley… - J Pharm Pharm …, 2007 - ualberta.ca
PURPOSE. The purpose of this study was to quantify the intestinal metabolism of
midazolam, a CYP P450 substrate, usually used as a probe for the activity of the isoform …

Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?

A Smits, RFW De Cock, V Cossey… - Biomarkers in …, 2012 - Taylor & Francis
Aim: Large interindividual variability in neonatal propofol clearance is documented which, in
part, can be explained by postmenstrual age (PMA) and postnatal age (PNA). We aimed to …